의료용 폴리글리콜산 시장 : 시장 예측(2026-2032년)

The Medical Polyglycolic Acid Market is projected to grow by USD 2.49 billion at a CAGR of 8.73% by 2032.

Medical Polyglycolic Acid: Executive Overview

Medical polyglycolic acid (PGA) is a biodegradable synthetic polymer used in absorbable sutures, tissue-engineering scaffolds, drug-delivery systems, and selected medical devices. Its clinical relevance derives from hydrolytic degradation, established processing routes, and the ability to tailor mechanical performance and resorption behavior through copolymerization, formulation, and device design. Adoption is shaped by regulatory requirements, biocompatibility evidence, sterilization compatibility, and the fit between degradation kinetics and the intended clinical application.

How Biodegradable Materials Are Reshaping Medical Devices

The medical-device landscape is shifting toward materials that support temporary clinical function while reducing the need for removal procedures. PGA contributes to this transition through predictable degradation and established use in absorbable products, while blended and copolymeric systems help address brittleness, rapid loss of strength, or application-specific handling requirements. Manufacturers are also placing greater emphasis on traceability, process validation, particulate control, and lifecycle documentation as regulators and healthcare providers scrutinize material safety and consistency.

Artificial Intelligence Accelerates Material and Device Development

Artificial intelligence is increasingly useful across the PGA value chain, although it does not replace laboratory, preclinical, or clinical validation. Machine-learning models can help relate polymer composition, molecular weight, processing conditions, sterilization exposure, and degradation profiles to target performance. AI-supported imaging and analytics may also improve evaluation of wound healing, scaffold integration, and device performance. The principal constraints remain limited high-quality datasets, explainability, cybersecurity, model validation, and the need to maintain compliance with medical-device quality systems.

Regional Dynamics Across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific

North America is characterized by mature medical-device regulation, advanced surgical infrastructure, and strong demand for documented biocompatibility and manufacturing controls. Europe emphasizes harmonized quality practices, clinical evidence, sustainability, and compliance with the Medical Device Regulation framework. Asia-Pacific combines substantial manufacturing capacity with expanding healthcare access and research activity, while regulatory pathways differ considerably across markets. Latin America is shaped by public and private healthcare investment, import dependence in several markets, and uneven approval timelines. The Middle East is strengthening specialized healthcare capacity and procurement systems, whereas Africa presents diverse opportunities linked to surgical access, local manufacturing capability, affordability, and supply-chain resilience.

Strategic Implications Across ASEAN, BRICS, the European Union, G7, GCC, and NATO

ASEAN markets require attention to varied regulatory systems, healthcare access, and cross-border supply chains. BRICS economies combine large and diverse healthcare systems with growing domestic manufacturing and research capabilities, but policy and reimbursement conditions differ materially. The European Union benefits from regulatory coordination while requiring rigorous conformity, clinical, and quality documentation. G7 members generally maintain sophisticated clinical infrastructure and demanding evidence standards. GCC countries are investing in advanced healthcare capacity and can serve as regional procurement and distribution hubs. NATO members, viewed collectively, also place importance on resilient medical supply chains, interoperability, and continuity of care during emergencies; however, this group is not a uniform regulatory or commercial market.

Country-Level Considerations for Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Russia, South Korea, Spain, the United Kingdom

Australia and Canada emphasize structured device review, quality systems, and evidence suitable for regulated healthcare environments. Brazil and Mexico require careful navigation of national registration, procurement, and import processes. China and India combine expanding medical-device capabilities with complex, evolving regulatory and localization considerations. Japan and South Korea place strong weight on technical documentation, clinical suitability, and advanced manufacturing quality. France, Germany, Italy, and Spain operate within the European regulatory environment while differing in procurement and healthcare implementation. The United Kingdom maintains a distinct post-EU regulatory pathway and strong clinical governance. Russia presents additional considerations involving domestic supply, regulatory change, logistics, and international trade constraints. Across all countries, successful deployment depends on validated degradation behavior, sterilization performance, local compliance, and reliable supply.

Priorities for Leaders in Medical Polyglycolic Acid

Industry leaders should first align polymer selection with the clinical endpoint, explicitly documenting degradation kinetics, strength retention, inflammatory response, and sterilization effects. They should build a modular evidence package covering raw-material controls, molecular characterization, extractables and leachables, biocompatibility, process validation, and post-market surveillance. Partnerships with hospitals and academic laboratories can improve clinically relevant testing, while dual sourcing and regional qualification can reduce supply disruption. AI should be deployed selectively for formulation screening, process monitoring, and image-based assessment, with human review, dataset governance, and validation embedded in the quality system. Sustainability claims should be supported by lifecycle evidence rather than assumptions about biodegradability.

Research Methodology for the Medical Polyglycolic Acid Assessment

This executive summary uses a structured qualitative assessment of medical PGA applications, material characteristics, regulatory considerations, technology developments, and geographic healthcare conditions. The approach distinguishes established clinical uses from emerging applications and evaluates adoption factors including biocompatibility, degradation behavior, processing, sterilization, quality assurance, reimbursement, procurement, and supply-chain resilience. Regional, group, and country perspectives are integrated to reflect differences in regulation, infrastructure, manufacturing, and access. No market estimates, market sizes, market shares, or forecasts are presented; conclusions are limited to evidence-based industry drivers, constraints, and strategic actions.

Conclusion: Building Reliable, Clinically Aligned PGA Platforms

Medical PGA remains relevant where temporary mechanical support, absorbability, and controllable degradation provide a clear clinical advantage. Its future application depends less on material novelty alone than on disciplined device design, robust evidence, regulatory readiness, and dependable manufacturing. Organizations that connect polymer science with clinical requirements, digital quality tools, regional compliance planning, and resilient sourcing will be better positioned to translate PGA capabilities into safe and practical medical solutions.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Medical Polyglycolic Acid Market, by Product Type

• 7.1. Introduction
• 7.2. Coated Filament
• 7.3. Filament Suture
  • 7.3.1. Monofilament
  • 7.3.2. Multifilament
• 7.4. Yarn

8. Medical Polyglycolic Acid Market, by Application

• 8.1. Introduction
• 8.2. Drug Delivery
  • 8.2.1. Implantable Systems
    • 8.2.1.1. Scaffolds
    • 8.2.1.2. Stents
  • 8.2.2. Microspheres
    • 8.2.2.1. Nanoparticles
    • 8.2.2.2. Polymer Beads
• 8.3. Surgical Sutures
  • 8.3.1. Cardiovascular Surgery
  • 8.3.2. General Surgery
  • 8.3.3. Gynecological Surgery
  • 8.3.4. Ophthalmic Surgery
  • 8.3.5. Orthopedic Surgery
• 8.4. Tissue Engineering
  • 8.4.1. Hard Tissue Engineering
    • 8.4.1.1. Bone Tissue
    • 8.4.1.2. Cartilage Tissue
  • 8.4.2. Soft Tissue Engineering
    • 8.4.2.1. Cardiac Tissue
    • 8.4.2.2. Dermal Tissue

9. Medical Polyglycolic Acid Market, by End User

• 9.1. Introduction
• 9.2. Ambulatory Surgical Centers
• 9.3. Clinics
• 9.4. Hospitals
• 9.5. Specialized Hospitals

10. Medical Polyglycolic Acid Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Distribution
• 10.3. Online Sales
• 10.4. Third Party Distributors

11. Medical Polyglycolic Acid Market, by Region

• 11.1. Introduction
• 11.2. Asia-Pacific
• 11.3. North America
• 11.4. Latin America
• 11.5. Europe
• 11.6. Middle East
• 11.7. Africa

12. Medical Polyglycolic Acid Market, by Group

• 12.1. Introduction
• 12.2. ASEAN
• 12.3. GCC
• 12.4. European Union
• 12.5. BRICS
• 12.6. G7
• 12.7. NATO

13. Medical Polyglycolic Acid Market, by Country

• 13.1. Introduction
• 13.2. United States
• 13.3. Canada
• 13.4. Mexico
• 13.5. Brazil
• 13.6. United Kingdom
• 13.7. Germany
• 13.8. France
• 13.9. Russia
• 13.10. Italy
• 13.11. Spain
• 13.12. China
• 13.13. India
• 13.14. Japan
• 13.15. Australia
• 13.16. South Korea

14. Competitive Landscape

• 14.1. Market Share Analysis, 2025
• 14.2. Market Concentration Analysis, 2025
  • 14.2.1. Concentration Ratio (CR)
  • 14.2.2. Herfindahl Hirschman Index (HHI)
• 14.3. Recent Developments & Impact Analysis, 2025
• 14.4. Product Portfolio Analysis, 2025
• 14.5. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Abbott Laboratories
• 15.2. Advance Medical Polymer Co., Ltd.
• 15.3. AmerisourceBergen Corporation
• 15.4. B. Braun Melsungen AG
• 15.5. BASF SE
• 15.6. BMG Incorporated
• 15.7. Corbion N.V.
• 15.8. DSM Biomedical
• 15.9. DuPont de Nemours, Inc.
• 15.10. Ethicon, Inc.
• 15.11. Evonik Industries AG
• 15.12. Foryou Medical
• 15.13. Goodfellow Cambridge Ltd.
• 15.14. Gunze Limited
• 15.15. Huizhou Foryou Medical Devices Co., Ltd.
• 15.16. Hunan Grand Poly Co., Ltd.
• 15.17. Kureha Corporation
• 15.18. Medtronic plc
• 15.19. Meta Biomed Co., Ltd.
• 15.20. Mitsubishi Chemical Corporation
• 15.21. Poly-Med, Inc.
• 15.22. Samyang Biopharm
• 15.23. Shanghai Pujing Chemical Industry Co., Ltd.
• 15.24. Shenzhen Polymtek Biomaterial Co., Ltd.
• 15.25. Synthetech Polymers, Inc.
• 15.26. Teleflex Incorporated
• 15.27. Tepha Inc.
• 15.28. W.L. Gore & Associates, Inc.
• 15.29. Zhejiang Hisun Biomaterials Co., Ltd.

16. Key Experts